Lazard World Dividend & Income Fund, Inc. (NYSE:LOR) has declared its monthly distribution of $0.07063 per common share. The company will pay the distribution on May 24, 2010. The record date for the dividend is May 12, 2010. The ex-dividend date is May 10, 2010.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Lorus Therapeutics reported a net loss of $1.3 million for the three months period ended February 28, 2010. This shows a decrease in the company’s net loss from the previous year’s net loss of $2.5 million. For the nine months period ended February 28, 2010, the company reported net earnings of $7.2 million. The year ago period had a net loss of $7.0 million.
Lazard World Dividend & Income Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is total return through a combination of dividends, income and capital appreciation. The Fund’s world equity portfolio is generally invested in 60 to 90 securities, consisting primarily of the highest dividend-yielding stocks selected from the holdings of other accounts managed by the Fund’s investment manager, Lazard Asset Management LLC. The equity portfolio is diversified in both developed and emerging market countries and across the capitalization spectrum. The Fund also seeks enhanced income through investing in high-yielding, short-duration, emerging market forward currency contracts and local currency debt instruments.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
